MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014
January 29, 2014 02:07 ET
|
MdxHealth (TM)
IRVINE, Calif. and HERSTAL, Belgium, Jan. 29, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to...
MDxHealth's MGMT Test Included in NCCN Guidelines and Awarded Tier 1 Reimbursement Code by AMA
October 16, 2013 02:22 ET
|
MdxHealth (TM)
IRVINE, Calif. and HERSTAL, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to...
MDxHealth's ConfirmMDx(R) Meets All Primary Endpoints in Blinded U.S. Clinical Validation Study
October 07, 2013 02:22 ET
|
MdxHealth (TM)
IRVINE, Calif. and HERSTAL, Belgium, Oct. 7, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to...
MDxHealth Insurance Agreements Expand Access to ConfirmMDx(R) for Prostate Cancer Test
October 01, 2013 02:27 ET
|
MdxHealth (TM)
IRVINE, Calif. and HERSTAL, Belgium, Oct. 1, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostics company that develops and commercializes epigenetic tests to...